1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,020 | 1,070 | 07:44 | |
| 1,020 | 1,070 | 07:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak | 212 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 11.03. | NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company | 737 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 04.03. | Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan | 569 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled "Measles outbreak is call to action for all of us".... ► Artikel lesen | |
| 19.02. | NanoViricides GAAP EPS of -$0.14 | 2 | Seeking Alpha | ||
| 19.02. | NanoViricides, Inc. Has Filed its Quarterly Report | 511 | ACCESS Newswire | Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (NYSE... ► Artikel lesen | |
| 14.02. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.02. | NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape | 653 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum... ► Artikel lesen | |
| 29.01. | NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025 | 679 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the... ► Artikel lesen | |
| 27.01. | NanoViricides Engages CRO for Phase II Clinical Trial | 868 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase... ► Artikel lesen | |
| 13.01. | NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 | 478 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 08.01. | NanoViricides: Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals | 648 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are... ► Artikel lesen | |
| 23.12.24 | NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape | 1.860 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential... ► Artikel lesen | |
| 12.12.24 | NANOVIRICIDES, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 15.11.24 | NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID | 592 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September... ► Artikel lesen | |
| 04.11.24 | NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am | 797 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 22.10.24 | NanoViricides President Dr. Diwan to Present at the PODD Conference | 437 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 15.10.24 | NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology | 606 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 08.10.24 | NanoViricides to Present at the Global AMR Summit 2024 Tomorrow | 576 | ACCESS Newswire | Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides... ► Artikel lesen | |
| 30.09.24 | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID | 614 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30... ► Artikel lesen | |
| 26.09.24 | NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs | 709 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that... ► Artikel lesen |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 22,550 | +4,16 % | Formycon: German Select: Pipeline-Updates stützen das Aufwärtsszenario; mwb bestätigt KAUFEN | Formycon präsentierte sich auf der 4. German Select Conference von mwb research und stellte Fortschritte in seiner Biosimilar-Pipeline vor. FYB202 wurde in den USA eingeführt, und FYB201 soll 2026 in... ► Artikel lesen | |
| ONTO INNOVATION | 109,00 | +1,87 % | EQS-Media: LPKF Laser & Electronics SE: Onto Innovation und LPKF treiben gemeinsam die Massenproduktion von Glassubstraten für Halbleiter voran | EQS-Media / 02.04.2025 / 09:00 CET/CEST
Onto Innovation und LPKF treiben gemeinsam die Massenproduktion von Glassubstraten für Halbleiter voran
LPKF schließt sich dem Packaging Applications... ► Artikel lesen | |
| SOLESENCE | 2,215 | 0,00 % | Solésence, Inc.: Solésence Announces Uplisting to Nasdaq | Trading set to begin Tuesday, April 8 under new ticker "SLSN" ROMEOVILLE, Ill., April 07, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions... ► Artikel lesen | |
| GAUZY | 8,800 | 0,00 % | GAUZY LTD: Gauzy Unveils 11,000sqft Smart Glass Projection Display in MSC's New Miami Terminal, the Largest Cruise Ship Terminal in the World | ||
| ZENTEK | 1,020 | +4,62 % | Zentek Announce Strategic Partnership with Filtration Solutions Industrial Co. to Manufacture and Distribute Graphene-Enhanced HVAC Filters | GUELPH, ON / ACCESS Newswire / April 14, 2025 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company, is pleased... ► Artikel lesen | |
| NVE | 50,50 | -1,94 % | Dividendenbekanntmachungen (03.02.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACUITY BRANDS INC US00508Y1029 0,17 USD 0,1641 EUR AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,0289 EUR AON PLC IE00BLP1HW54 0... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,396 | 0,00 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| OBDUCAT | 0,058 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025 | Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY... ► Artikel lesen | |
| ACACIA RESEARCH | 2,520 | +1,61 % | Acacia Research Reports Third Quarter 2024 Financial Results | NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) ("Acacia" or the "Company"), which acquires and operates businesses across the industrial, energy and technology sectors, today... ► Artikel lesen | |
| LEHNER INVESTMENTS | 0,032 | 0,00 % | EQS-Adhoc: LEHNER INVESTMENTS AG: Sonderprüfung gerichtlich angeordnet | EQS-Ad-hoc: LEHNER INVESTMENTS AG / Schlagwort(e): Rechtssache
LEHNER INVESTMENTS AG: Sonderprüfung gerichtlich angeordnet
04.04.2025 / 18:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| NANOFOCUS | 0,880 | 0,00 % | NanoFocus schließt Kapitalerhöhung ab | Die NanoFocus AG hat die beschlossene Kapitalerhöhung gegen Sach- und Bareinlagen durchgeführt. Insgesamt wurden 6.021.664 neue Aktien zu je 1,00 Euro ausgegeben. Davon gingen 4.276.884 Aktien an die... ► Artikel lesen | |
| RIBER | 2,330 | -0,85 % | RIBER reports solid growth in sales and earnings in 2024 | RIBER reports solid growth in sales and earnings in 2024 Revenues: €41.2m (+5%)Income from ordinary operations: €4.5m, representing 11% of revenues Net income: €4.1m (+21%)Proposed payout of €0.08... ► Artikel lesen | |
| GOMSPACE | 0,701 | 0,00 % | GOMSPACE GROUP AB: Notice to attend the annual general meeting in GomSpace Group AB (publ) | ||
| REGION GROUP | 1,198 | 0,00 % | REGION GROUP: Change of Registry Address Notification | ||
| XTPL | 24,050 | 0,00 % | EQS-News: XTPL S.A.: XTPL posts its highest-ever sales in Q4 2024 with growth prospects for 2025 | Issuer: XTPL S.A.
/ Key word(s): Preliminary Results/Sales Result
XTPL posts its highest-ever sales in Q4 2024 with growth prospects for 2025
22.01.2025 / 09:13 CET/CEST
The... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Der aktuelle Kurs liegt bei 0,900 Euro und damit +2,27 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.
